Hütter J - Search Results

1

Overexpression of PH-4, a novel putative proline 4-hydroxylase, modulates activity of hypoxia-inducible transcription factors.

Oehme F, Ellinghaus P, Kolkhof P, Smith TJ, Ramakrishnan S, Hütter J, Schramm M, Flamme I. Oehme F, et al. Among authors: hutter j. Biochem Biophys Res Commun. 2002 Aug 16;296(2):343-9. doi: 10.1016/s0006-291x(02)00862-8. Biochem Biophys Res Commun. 2002. PMID: 12163023

2

A new type of Ca-channel modulation by a novel class of 1,4-dihydropyridines.

Bechem M, Goldmann S, Gross R, Hallermann S, Hebisch S, Hütter J, Rounding HP, Schramm M, Stoltefuss J, Straub A. Bechem M, et al. Among authors: hutter j. Life Sci. 1997;60(2):107-18. doi: 10.1016/s0024-3205(96)00600-5. Life Sci. 1997. PMID: 9000116

3

Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT(2)) receptor.

Wunder F, Tinel H, Kast R, Geerts A, Becker EM, Kolkhof P, Hütter J, Ergüden J, Härter M. Wunder F, et al. Among authors: hutter j. Br J Pharmacol. 2010 May;160(2):399-409. doi: 10.1111/j.1476-5381.2010.00730.x. Br J Pharmacol. 2010. PMID: 20423349 Free PMC article.

4

Role of fatty acid metabolites in the development of myocardial ischemic damage.

Hütter JF, Soboll S. Hütter JF, et al. Int J Biochem. 1992 Mar;24(3):399-403. doi: 10.1016/0020-711x(92)90030-5. Int J Biochem. 1992. PMID: 1551453 Review.

5

Cardiovascular effects of a novel potent and highly selective azaindole-based inhibitor of Rho-kinase.

Kast R, Schirok H, Figueroa-Pérez S, Mittendorf J, Gnoth MJ, Apeler H, Lenz J, Franz JK, Knorr A, Hütter J, Lobell M, Zimmermann K, Münter K, Augstein KH, Ehmke H, Stasch JP. Kast R, et al. Among authors: hutter j. Br J Pharmacol. 2007 Dec;152(7):1070-80. doi: 10.1038/sj.bjp.0707484. Epub 2007 Oct 15. Br J Pharmacol. 2007. PMID: 17934515 Free PMC article.

6

PDE5 inhibitors beyond erectile dysfunction.

Sandner P, Hütter J, Tinel H, Ziegelbauer K, Bischoff E. Sandner P, et al. Among authors: hutter j. Int J Impot Res. 2007 Nov-Dec;19(6):533-43. doi: 10.1038/sj.ijir.3901577. Epub 2007 Jul 12. Int J Impot Res. 2007. PMID: 17625575 Review.

7

Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms.

Tinel H, Stelte-Ludwig B, Hütter J, Sandner P. Tinel H, et al. Among authors: hutter j. BJU Int. 2006 Dec;98(6):1259-63. doi: 10.1111/j.1464-410X.2006.06501.x. Epub 2006 Sep 6. BJU Int. 2006. PMID: 16956354

8

A cell-based cGMP assay useful for ultra-high-throughput screening and identification of modulators of the nitric oxide/cGMP pathway.

Wunder F, Stasch JP, Hütter J, Alonso-Alija C, Hüser J, Lohrmann E. Wunder F, et al. Among authors: hutter j. Anal Biochem. 2005 Apr 1;339(1):104-12. doi: 10.1016/j.ab.2004.12.025. Anal Biochem. 2005. PMID: 15766716

9

Design and synthesis of potent and selective azaindole-based Rho kinase (ROCK) inhibitors.

Schirok H, Kast R, Figueroa-Pérez S, Bennabi S, Gnoth MJ, Feurer A, Heckroth H, Thutewohl M, Paulsen H, Knorr A, Hütter J, Lobell M, Münter K, Geiss V, Ehmke H, Lang D, Radtke M, Mittendorf J, Stasch JP. Schirok H, et al. Among authors: hutter j. ChemMedChem. 2008 Dec;3(12):1893-904. doi: 10.1002/cmdc.200800211. ChemMedChem. 2008. PMID: 18973168

10

Action of synthetic atrial natriuretic factor on contractility and coronary perfusion in isolated working rat hearts.

Hütter JF. Hütter JF. Eur J Pharmacol. 1991 Jan 25;193(1):127-9. doi: 10.1016/0014-2999(91)90212-9. Eur J Pharmacol. 1991. PMID: 1828766

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

586 results

Search Page